Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis maintains a conservative capital structure with a debt-to-equity ratio of 0.41, below the median for its industry, and a current ratio of 1.14, indicating moderate liquidity. However, the company's cash and equivalents of INR 100 million are insufficient to cover its long-term debt of INR 23.89 billion, resulting in a negative net cash position. Profitability metrics are weak, with a return on equity of 0.06% and a return on assets of 0.03%, both significantly below the industry median. The company's operating income of INR 1.68 billion represents a narrow margin of 6.2% of revenue, suggesting limited pricing power or cost control. The company's revenue is split between its CRAMS and Marketable Molecules segments, with no disclosed geographic revenue breakdown. However, its manufacturing and research facilities are spread across India, Switzerland, France, the Netherlands, the United Kingdom, and China, indicating a diversified geographic footprint. Growth appears constrained, with no significant revenue growth reported in the latest financial period. The company's capital expenditures of INR 2.17 billion were negative, suggesting asset disposals or reduced investment in infrastructure. The outlook for the next fiscal year remains uncertain without disclosed growth initiatives. The company faces moderate liquidity risk due to its negative net cash position and a medium risk of dilution, though the probability is currently low. No recent dilutive events have been disclosed, and the company has not issued additional shares in the past year. Recent filings and transcripts have not disclosed any material events that would significantly alter the company's financial or operational trajectory. The company continues to operate within its disclosed segments and has not announced any major strategic shifts.